Development of Coxsackievirus B3 as an Oncolytic Virus for KRAS-Mutant Lung Cancer Treatment

In Canada, lung cancer is the leading cause of cancer-related deaths for both sexes. Non-small-cell lung cancer (NSCLC) constitutes ~85% of lung cancer cases. Mutations in the KRAS and EGFR genes are two most common oncogenic drivers for NSCLC and responsible for ~30% and ~15% of NSCLCs, respectively. Unlike the EGFR-mutant type, KRAS-mutant NSCLC is currently undruggable and associated with poor prognosis. Our lab has recently demonstrated that Coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS-mutant NSCLC.

The development of a novel oncolytic virotherapy for acute myeloid leukemia

Modern molecularly targeted therapies have shown promise in treating some blood cancers, but a cure remains elusive for most acute blood cancer patients. This is largely due to the survival of some blood cancer cells that possess unique properties and can cause treatment failure or relapse, highlighting the need for new therapies. In collaboration with Virogin Biotech Ltd, we aim to develop an innovative oncolytic virotherapy to effectively target acute myeloid leukemia (AML) patient cells that are resistant to current therapies.

Development of Coxsackievirus B3 as an Oncolytic Virus for KRAS-Mutant Lung Cancer Treatment

In Canada, lung cancer is the leading cause of cancer-related deaths for both sexes. Non-small-cell lung cancer (NSCLC) constitutes ~85% of lung cancer cases. Mutations in the KRAS and EGFR genes are two most common oncogenic drivers for NSCLC and responsible for ~30% and ~15% of NSCLCs, respectively. Unlike the EGFR-mutant type, KRAS-mutant NSCLC is currently undruggable and associated with poor prognosis. Our lab has recently demonstrated that Coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS-mutant NSCLC.

Oncolytic HSV-1 (oHSV-1) for treatment of prostate cancer

This project is to use genetic engineered “cold-sore” virus to treat prostate cancer. The virus is engineered to reduce its toxicity to normal tissues but can specifically attack and kill tumour cells. Meanwhile, the virus releases a group of anti-tumour immune stimulating factors to activate immune system to eliminate prostate tumour. This project will use a unique prostate tumour mouse model to test the virus.